BREAKING NEWS: New FDA Approval for Generalized Myasthenia Gravis (gMG)

[Muscular Dystrophy Association]( [BREAKING NEWS: New Drug Approval for Generalized Myasthenia Gravis ]( MDA celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Zilucoplan is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG, and it is the only once-daily gMG-target therapy for self-administration. Zilucoplan will be made available in the United States by [UCB](. "The recent approval of zilucoplan is great news for people living with gMG,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA. “This is the second gMG therapy out of UCB that has achieved FDA approval this year, providing patients and physicians with important options. It is also the first and only self-administered therapeutic of its kind, greatly improving access, convenience, and independence for those living with and managing the disease.” [Read the Full Announcement]( “People living with gMG can experience a variety of serious problems, including drooping eyelids, double vision, and difficulty swallowing, chewing, and talking. In some severe cases, patients may even experience life-threatening weakening of respiratory muscles,” said Barry Byrne, M.D., Ph.D., Chief Medical Advisor, MDA and Associate Chair of Pediatrics and Director of the Powell Gene Therapy Center at the University of Florida. “A particularly challenging disease to treat and manage, it is wonderful that we are now adding this new therapy to the community’s toolkit.” MDA’s Investment in MG Research Since its inception, MDA has invested nearly $57 million in [myasthenia gravis (MG)]( research. [Learn More]( Today’s celebration of this groundbreaking treatment is possible because of dedicated donors to MDA who help bring treatments like this to market for people living with neuromuscular disease. Please consider making a donation to MDA to continuing bringing research to reality. [Continue the Impact](. --------------------------------------------------------------- [Facebook]( [Twitter]( [Instagram]( [LinkedIn]( [YouTube]( [MDA.org]( © 2023 Muscular Dystrophy Association, Inc.. All rights reserved. 1016 W Jackson Blvd #1073 Chicago, IL 60607 1-800-572-1717 [Unsubscribe]( | [State Fundraising Notices]( The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization. [View Online]( | [Subscription Center]( | [Privacy Policy](